Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL) has completed enrollment for its Phase II/III trial of SLS-005, a treatment for amyotrophic lateral sclerosis (ALS), with 160 participants. The study is randomized, double-blind, and placebo-controlled, focusing on the efficacy of SLS-005 over 24 weeks, with topline data expected in late 2023. Additionally, Seelos plans to launch an Expanded Access Program, funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS), to provide SLS-005 to 70 ALS patients who do not qualify for other trials. SLS-005 has received Orphan Drug Designation for ALS treatment.

Positive

• Completion of enrollment for Phase II/III trial of SLS-005, marking a significant milestone.
• Topline data from the trial expected in the second half of 2023.
• Expanded Access Program to enroll 70 patients, providing access to treatment for those unable to join ongoing trials.

Negative

• None.

- The randomized, double-blind, placebo-controlled study is evaluating SLS-005 in 160 patients over 24 weeks and Seelos anticipates delivering topline data in the second half of 2023.

- Seelos will also enroll patients in an Expanded Access Program that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Accelerating Access for Critical Therapies for ALS Act (ACT for ALS).

NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the completion of enrollment of its registrational Phase II/III trial studying the investigational treatment SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) on the HEALEY ALS Platform Trial.

"The full enrollment of this study is a significant milestone for Seelos. We look forward to releasing the topline data later this year and initiating the Expanded Access Program later this quarter," said Raj Mehra Ph.D., Chairman and CEO of Seelos. "We would like to offer our gratitude to the ALS community for its support and to the team at Healey & AMG Center for ALS at Mass General and the clinical trial sites in the Northeast ALS Consortium for their hard work and commitment in running this innovative platform trial. We also thank the NINDS for the financial support of the Expanded Access Program grant under the ACT for ALS."

Seelos' Phase II/III trial (NCT05136885) has enrolled 160 participants with either familial or sporadic ALS in a double-blind placebo-controlled trial. Participants were randomized 3:1 (drug: placebo), with the primary endpoint measuring change from baseline on Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at 24 weeks. Secondary endpoints include change from baseline in slow vital capacity, muscle strength, quality of life measurements as well as additional signs of disease progression. 

Seelos plans to initiate an Expanded Access Program (EAP) late in the first quarter of this year that is fully funded by a grant from the NINDS under the ACT for ALS.

Under this EAP, Seelos plans to enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS who do not qualify for other ongoing clinical trials, thus offering these patients an experimental treatment that they may not otherwise have access to.

If you are a patient (PALS) or caregiver of someone with ALS (CALS) and would like more information, please visit: https://seelostherapeutics.com/patients-and-caregivers/

About SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion)

SLS-005 is a low molecular weight disaccharide (0.342 kDa) that crosses the blood brain barrier and is thought to stabilize proteins and activate autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material. In animal models of several diseases associated with abnormal cellular protein aggregation or storage of pathologic material, SLS-005 has been shown to reduce aggregation of misfolded proteins and reduce accumulation of pathologic material. SLS-005 has previously received Orphan Drug Designation for the treatment of ALS from the U.S. Food and Drug Administration and from the European Medicines Agency in the EU. SLS-005 is an investigational treatment and is not currently approved by any health authority for medicinal use.

About Amyotrophic Lateral Sclerosis (ALS)

According to the National Institute of Neurological Disorders and Stroke, amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (called atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The disease is progressive, meaning the symptoms get worse over time. The majority of ALS cases (90 percent or more) are considered sporadic. This means the disease seems to occur at random with no clearly associated risk factors and no family history of the disease. Although family members of people with sporadic ALS are at an increased risk for the disease, the overall risk is very low, and most will not develop ALS.

Most people with ALS eventually die from respiratory failure, usually within 3 to 5 years from when the symptoms first appear. However, about 10 percent of people with ALS survive for 10 or more years. Currently, there is no cure for ALS and no effective treatment to halt or reverse, the progression of the disease.

About the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)

The ACT for ALS, Public Law 117-79, among other things, requires the Department of Health and Human Services (HHS), through the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), to implement a Public-Private Partnership for Rare Neurodegenerative Diseases through cooperative agreements or contracts to advance the understanding of neurodegenerative diseases and foster development of treatments for ALS and other rare neurodegenerative diseases. It requires the FDA to publish and implement a 5-year action plan to foster drug development and facilitate access to investigational drugs for ALS and other rare neurodegenerative diseases. Finally, it requires that the FDA award grants or contracts to public and private entities to cover costs of research on, and development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children.

More information on ACT for ALS is available here.

More information about NINDS is available here.

Forward Looking Statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding Seelos' Registrational Phase II/III Trial of SLS-005 treatment of ALS (the "Trial"), the expected timing for releasing the topline data from the Trial, the expected timing for initiating the EAP, the number of patients to be enrolled in the EAP, the expected duration of the EAP, statements regarding SLS-005's prospects and potential and statements regarding the Company's potential market opportunity. These statements are based on Seelos' current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business and plans described herein include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies, or continuing the Trial or commencing the EAP, and not gaining marketing approvals for its product candidates, the risk that prior clinical results may not be replicated in future studies and trials (including the risk that the results from the prior studies of SLS-005 may not be replicated or may be materially different from the results of the Trial, the EAP or other future trails and studies of SLS-005), the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of Seelos' business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos' current stock price, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos' periodic filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact Information:

Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 2^nd Floor
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/
https://twitter.com/seelostx 
https://www.linkedin.com/company/seelos

Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-completion-of-enrollment-of-its-phase-iiiii-trial-of-sls-005-in-amyotrophic-lateral-sclerosis-on-the-healey-als-platform-301744494.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What is the current status of Seelos Therapeutics' SLS-005 trial for ALS?

Seelos Therapeutics has completed enrollment for its Phase II/III trial of SLS-005, with results expected in late 2023.

How many patients are involved in the Phase II/III trial of SLS-005?

The trial involves 160 patients diagnosed with ALS.

What is the purpose of the Expanded Access Program from Seelos Therapeutics?

The Expanded Access Program aims to provide SLS-005 to 70 ALS patients who do not qualify for other clinical trials.

When is the topline data for SLS-005 expected to be released?

Topline data for SLS-005 is anticipated in the second half of 2023.

What designation has SLS-005 received for ALS treatment?

SLS-005 has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency.